Description: Cytoskeletal Proteins in Neurodegenerative Diseases, Volume 150 covers the pivotal roles that cytoskeletal proteins play in the onset and progression of neurodegenerative disorders. The book explores the structure, function, and dynamics of key cytoskeletal components--including microtubules, actin filaments, and intermediate filaments--and examines how their dysfunction contributes to diseases such as Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis (ALS). Chapters in this new release include Cytoskeletal proteins regulates Tau in Alzheimer's Disease, "Sticks with whips in neurodegenerative diseases: On the roles of intrinsic disorder in (dis)function of cytoskeletal proteins", Glial Fibrillary Protein is potential biomarker For AD, and much more.
Additional chapters cover Cytoskeletal disintegration in cardiovascular disease-related neurodegeneration, Cytoskeletal Proteins in Neurodegeneration, Extracellular matrix degradation proteins in Neurodegenerative disease, GPCRs regulates Cytoskeletal remodeling in microglia, Understanding the impact of cytoskeleton disruption on synaptic plasticity in Alzheimer's Disease, Chemokine receptors modulates Cytoskeletal proteins in Alzheimer's disease, Cytoskeletal Intermediate Filament proteins in Neurodegeneration, Mechanism of tau proteins differentially regulating the motility of different families of kinesin motors, The Quest to Restore Neuronal Structure: Targeting Cytoskeletal Proteins in Neurodegenerative Diseases, and many more timely topics.Brief description: Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.